Pharmacokinetics and Dose‐Proportionality of Oxymorphone Extended Release and Its Metabolites: Results of a Randomized Crossover Study

200465 citationsJournal Articlebronze Open Access

Authors

Michael P. Adams · Fisher Bioservices (United States)

Harry Ahdieh · Endo Pharmaceuticals (United States)

Abstract

The pharmacokinetic profile of oxymorphone ER demonstrates linearity and dose-proportionality under single-dose and steady-state conditions for the parent compound and its metabolites for doses of 5-40 mg.

Topics & Keywords

Pain Management and Opioid Use Opioid Use Disorder Treatment Pain Mechanisms and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Volume 24, Issue 4, pp. 468-476

DOI: 10.1592/phco.24.5.468.33347

Field-Weighted Citation Impact: 6.96